Is vaping linked to chronic stress in teens and young adults?
Young people who have used e-cigarettes are more than twice as likely to report experiencing chronic stress, according to research Dr Teresa To from the Hospital for Sick… read more.
Young people who have used e-cigarettes are more than twice as likely to report experiencing chronic stress, according to research Dr Teresa To from the Hospital for Sick… read more.
A large study published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.230459 identified 10 predictors of opioid overdose after prescription for chronic pain, which can help clinicians engage in shared decision-making with patients… read more.
The cells of babies exposed to air pollution while in the womb show damage which may put them at risk of ill-health later in life, according to research… read more.
Survival rates for men with metastatic prostate cancer have increased by an average of six months, something which coincides with the gradual introduction of ‘dual treatment’ since 2016,… read more.
The European Medicines Agency (EMA) has recommended seven medicines for approval at its October 2023 meeting. The brings the total number of newly approved medicines this year to… read more.
The European Medicines Agency (EMA) has adopted revised transparency rules for the publication of information on clinical trials submitted through the Clinical Trials Information System (CTIS). The changes give access… read more.
An open-label, international study published in the New England Journal of Medicine found that patients receiving Spravato (esketamine) CIII nasal spray for treatment-resistant depression (TRD) were 1.54 times… read more.
Of the 198 new oncology drugs approved by the U.S. Food and Drug Administration (FDA) between 1998 and 2022, approximately 43% were precision oncology therapies, the use of… read more.
Researchers report that patients treated for treatment-resistant depression with esketamine NS (nasal spray), a form of ketamine, achieve better and more durable outcomes than similar patients treated with… read more.
STEP-HFpEF was a randomised, controlled trial designed to find out whether semaglutide for 52 weeks could improve heart failure symptoms and physical function in obese, non-diabetic patients with… read more.
An American born in 2019 will spend a larger share of their lifetime taking prescription drugs than being married or receiving an education, according to new research by… read more.
The results of the STEP-HFpEF trial point towards routine use of GLP-1 agonists in heart failure but this has to be balanced against conflicting guidelines and cost pressures… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.